MediMedia Managed Markets
Managed Care magazine
P&T Community, The Online Resource for P&T Decision Makers
Login / Register
Join Us  Facebook  Twitter  Linked In


News Categories




Daclatasvir/Asunaprevir Combo Receives ‘Breakthrough Therapy’ Designation for Hepatitis C

Treatment targets genotype 1b HCV (February 24)

The FDA has granted the dual regimen of daclatasvir and asunaprevir (Bristol-Myers Squibb) a “breakthrough therapy” designation for use in the treatment of genotype 1b chronic hepatitis C virus (HCV) infection.

The designation was based on data from an ongoing phase III clinical trial program evaluating the all-oral combination regimen of daclatasvir, an investigational NS5A replication complex inhibitor, and asunaprevir, an investigational NS3 protease inhibitor, without ribavirin.

According to the FDA, a breakthrough therapy designation is intended to expedite the development and review of drugs for serious or life-threatening conditions.

An estimated 2.7 to 3.9 million people are chronically infected with HCV in the U.S.

Source: Bristol-Myers Squibb; February 24, 2014.

More stories